(LXRX) Lexicon Pharmaceuticals - Ratings and Ratios
Diabetes, Heart, Kidney, Pain, Obesity
LXRX EPS (Earnings per Share)
LXRX Revenue
Description: LXRX Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) is a biopharmaceutical company focused on discovering, developing, and commercializing treatments for various human diseases. The companys lead product, Sotagliflozin, is an orally-delivered small molecule drug aimed at reducing cardiovascular risks in adults with heart failure, type 2 diabetes, and chronic kidney disease.
Key pipeline assets include Sotagliflozin for hypertrophic cardiomyopathy and type 1 diabetes (Phase 3), LX9211 for neuropathic pain (completed Phase II), and LX9851 for obesity and cardiometabolic disorders. Strategic collaborations with Viatris Inc. and Bristol-Myers Squibb Company are in place to further development and commercialization efforts.
From a financial perspective, Lexicon Pharmaceuticals has a market capitalization of $337.50M USD, indicating a relatively small-cap company. The absence of a P/E ratio suggests that the company is not yet profitable. Return on Equity (RoE) stands at -103.16, highlighting significant investor losses. To turn the company around, key performance indicators (KPIs) to watch include Sotagliflozins commercialization progress, LX9211 and LX9851s clinical trial results, and the companys cash burn rate.
Additional KPIs to monitor include the companys research and development (R&D) expenses as a percentage of revenue, operating cash flow, and the debt-to-equity ratio. A thorough analysis of these metrics will help investors gauge the companys financial health, managements ability to execute on its pipeline, and the potential for future growth.
LXRX Stock Overview
| Market Cap in USD | 407m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2000-04-07 |
LXRX Stock Ratings
| Growth Rating | -58.6% |
| Fundamental | 35.0% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -40.3% |
| Analyst Rating | 3.80 of 5 |
LXRX Dividends
Currently no dividends paidLXRX Growth Ratios
| Growth Correlation 3m | 52.1% |
| Growth Correlation 12m | -23% |
| Growth Correlation 5y | -72.7% |
| CAGR 5y | -24.29% |
| CAGR/Max DD 3y | -0.26 |
| CAGR/Mean DD 3y | -0.46 |
| Sharpe Ratio 12m | -0.68 |
| Alpha | -50.15 |
| Beta | 0.867 |
| Volatility | 76.64% |
| Current Volume | 1688k |
| Average Volume 20d | 1606k |
| Stop Loss | 1 (-13%) |
| Signal | 1.45 |
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income (-120.6m TTM) > 0 and > 6% of Revenue (6% = 3.51m TTM) |
| FCFTA -0.80 (>2.0%) and ΔFCFTA -36.22pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 188.7% (prev 8046 %; Δ -7858 pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.45 (>3.0%) and CFO -101.9m > Net Income -120.6m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 4.16 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (363.6m) change vs 12m ago 16.97% (target <= -2.0% for YES) |
| Gross Margin 98.87% (prev 84.48%; Δ 14.39pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 19.51% (prev 0.98%; Δ 18.54pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -8.78 (EBITDA TTM -109.8m / Interest Expense TTM 12.6m) >= 6 (WARN >= 3) |
Altman Z'' -49.74
| (A) 0.49 = (Total Current Assets 145.1m - Total Current Liabilities 34.8m) / Total Assets 225.6m |
| (B) -8.82 = Retained Earnings (Balance) -1.99b / Total Assets 225.6m |
| warn (B) unusual magnitude: -8.82 — check mapping/units |
| (C) -0.37 = EBIT TTM -110.4m / Avg Total Assets 299.5m |
| (D) -20.69 = Book Value of Equity -1.99b / Total Liabilities 96.1m |
| Total Rating: -49.74 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 35.00
| 1. Piotroski 1.50pt = -3.50 |
| 2. FCF Yield -55.32% = -5.0 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.44 = 2.40 |
| 5. Debt/Ebitda -0.52 = -2.50 |
| 6. ROIC - WACC -55.77% = -12.50 |
| 7. RoE -83.63% = -2.50 |
| 8. Rev. Trend 91.44% = 4.57 |
| 9. Rev. CAGR 1005 % = 2.50 |
| 10. EPS Trend 60.74% = 1.52 |
| 11. EPS CAGR 0.0% = 0.0 |
What is the price of LXRX shares?
Over the past week, the price has changed by +6.48%, over one month by -2.54%, over three months by +71.64% and over the past year by -29.45%.
Is Lexicon Pharmaceuticals a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of LXRX is around 1.00 USD . This means that LXRX is currently overvalued and has a potential downside of -13.04%.
Is LXRX a buy, sell or hold?
- Strong Buy: 1
- Buy: 2
- Hold: 2
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the LXRX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 2.8 | 139.1% |
| Analysts Target Price | 2.8 | 139.1% |
| ValueRay Target Price | 1.1 | -3.5% |
Last update: 2025-09-04 04:42
LXRX Fundamental Data Overview
CCE Cash And Equivalents = 139.0m USD (Cash And Short Term Investments, last quarter)
P/S = 6.9655
P/B = 3.1444
P/EG = -0.14
Beta = 1.177
Revenue TTM = 58.4m USD
EBIT TTM = -110.4m USD
EBITDA TTM = -109.8m USD
Long Term Debt = 56.1m USD (from longTermDebt, last quarter)
Short Term Debt = 909.0k USD (from shortTermDebt, last quarter)
Debt = 57.0m USD (Calculated: Short Term 909.0k + Long Term 56.1m)
Net Debt = 40.1m USD (from netDebt column, last quarter)
Enterprise Value = 325.0m USD (407.0m + Debt 57.0m - CCE 139.0m)
Interest Coverage Ratio = -8.78 (Ebit TTM -110.4m / Interest Expense TTM 12.6m)
FCF Yield = -55.32% (FCF TTM -179.8m / Enterprise Value 325.0m)
FCF Margin = -307.7% (FCF TTM -179.8m / Revenue TTM 58.4m)
Net Margin = -206.4% (Net Income TTM -120.6m / Revenue TTM 58.4m)
Gross Margin = 98.87% ((Revenue TTM 58.4m - Cost of Revenue TTM 658.0k) / Revenue TTM)
Tobins Q-Ratio = -0.16 (set to none) (Enterprise Value 325.0m / Book Value Of Equity -1.99b)
Interest Expense / Debt = 4.07% (Interest Expense 2.32m / Debt 57.0m)
Taxrate = 21.0% (US default)
NOPAT = -110.4m (EBIT -110.4m, no tax applied on loss)
Current Ratio = 4.16 (Total Current Assets 145.1m / Total Current Liabilities 34.8m)
Debt / Equity = 0.44 (Debt 57.0m / last Quarter total Stockholder Equity 129.4m)
Debt / EBITDA = -0.52 (Net Debt 40.1m / EBITDA -109.8m)
Debt / FCF = -0.32 (Debt 57.0m / FCF TTM -179.8m)
Total Stockholder Equity = 144.2m (last 4 quarters mean)
RoA = -53.47% (Net Income -120.6m, Total Assets 225.6m )
RoE = -83.63% (Net Income TTM -120.6m / Total Stockholder Equity 144.2m)
RoCE = -55.13% (Ebit -110.4m / (Equity 144.2m + L.T.Debt 56.1m))
RoIC = -47.30% (NOPAT -110.4m / Invested Capital 233.5m)
WACC = 8.47% (E(407.0m)/V(464.0m) * Re(9.21%)) + (D(57.0m)/V(464.0m) * Rd(4.07%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 98.47 | Cagr: 6.88%
Discount Rate = 9.21% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -179.8m)
Revenue Correlation: 91.44 | Revenue CAGR: 1005 %
Rev Growth-of-Growth: -21.49
EPS Correlation: 60.74 | EPS CAGR: 0.0%
EPS Growth-of-Growth: 120.1
Additional Sources for LXRX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle